<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Occupational rhinitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Occupational rhinitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Occupational rhinitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Lotz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raymond G Slavin, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Corren, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Occupational rhinitis (OR) is defined as "an inflammatory condition of the nose, which is characterized by intermittent or persistent symptoms (ie, nasal congestion, sneezing, rhinorrhea, itching) and/or variable nasal airflow limitation and/or hypersecretion, due to causes and conditions attributable to a particular work environment and not to stimuli encountered outside of the workplace" [<a href="#rid1">1</a>]. OR can develop in response to dusts, gases, fumes, and vapors and may be classified as immunologic or nonimmunologic depending upon the mechanism involved in the pathogenesis of symptoms [<a href="#rid2">2,3</a>]. OR induced by immunologic sensitization to a specific substance is termed sensitizer-induced OR while OR occurring via exposure to high levels of irritants is termed irritant-induced rhinitis (IIR) [<a href="#rid4">4</a>]. OR should be differentiated from work-exacerbated rhinitis (WER), which is preexisting or concurrent (allergic or nonallergic) rhinitis that is worsened by but not caused by workplace exposures.</p><p>OR may have a profound effect on the worker, resulting in performance deficits, reduced productivity, and psychosocial problems. OR often coexists with occupational asthma (OA) and may precede and predict the development of OA [<a href="#rid5">5-8</a>].</p><p>The epidemiology, pathophysiology, clinical manifestations, diagnosis, and management of OR will be discussed here. OA is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/550.html" rel="external">"Occupational asthma: Clinical features, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/538.html" rel="external">"Occupational asthma: Pathogenesis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Occupational allergic diseases are common and appear to be increasing, with an estimated worldwide prevalence of 5 to 15 percent [<a href="#rid9">9,10</a>]. The prevalence of OR specifically is not precisely known, although it appears to be two to three times more prevalent than occupational asthma (OA) [<a href="#rid11">11,12</a>]. Prevalence estimates of OR vary with the methods used for diagnosis (questionnaire, objective evaluation), the occupation studied, and the geographic area in question (which may have distinctive industries).</p><p>The following factors complicate prevalence studies of OR:</p><p class="bulletIndent1"><span class="glyph">●</span>Rhinitis from all causes is a common disorder in the general population. Studies should include a control group of workers from the same population who are employed in a different and low-risk occupation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Questionnaires (without objective testing for sensitization to occupational allergens or direct nasal challenges with the suspect agent) are less reliable because there are numerous causes of rhinitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most accurate studies confirm the patient's reactivity using direct nasal challenges and an objective means of quantitating the patient's response. Nasal challenge procedures are reviewed below. (See <a class="local">'Direct nasal challenge'</a> below.)</p><p></p><p>The following studies estimated OR in specific occupations and illustrate the importance of confirmatory nasal challenge:</p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory employees who work with animals are one of the groups most commonly affected by OR and/or asthma. More than 40 percent of 156 workers reported rhinitis symptoms in one study, with 51 percent demonstrating skin test reactivity to laboratory animals [<a href="#rid13">13</a>]. A positive nasal challenge was found in 15 percent of those with symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 1021 tobacco workers found that 27 percent reported rhinitis, compared with 18 percent of controls (hospital workers) [<a href="#rid14">14</a>]. A positive nasal challenge study was documented in 70 percent of those with symptoms.</p><p></p><p>Bias also complicates prevalence studies. Underestimation may occur due to the healthy worker effect, which is a source of bias caused by the phenomenon that sicker individuals may choose work environments in which exposures are low or may be excluded from being hired. Similarly, already-hired workers may seek transfer to jobs with less exposure or leave work altogether [<a href="#rid15">15</a>]. This is the most common selection bias in occupational studies. Underestimation may also occur because of workers' reluctance to report symptoms for fear of losing employment.</p><p class="headingAnchor" id="H5"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The following preexistent symptoms and conditions have been implicated as risk factors for the development of OR:</p><p class="bulletIndent1"><span class="glyph">●</span>Other atopic disorders, particularly allergic rhinitis and asthma [<a href="#rid13">13,16,17</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>A high level of total immunoglobulin (Ig)E (&gt;150 k international units/L) [<a href="#rid18">18</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Level of exposure to known sensitizing agents and irritants in the workplace [<a href="#rid11">11,19</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Nonspecific nasal symptoms [<a href="#rid20">20</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory symptoms upon exposure to dust or strong odors [<a href="#rid17">17</a>]</p><p></p><p>Smoking has not been established as a risk factor for OR, although it does increase the risk of developing some forms of occupational asthma (OA). The relationship between duration of exposure to an occupational agent and the development of OR has not been extensively studied. (See  <a class="medical medical_review" href="/z/d/html/537.html" rel="external">"Occupational asthma: Definitions, epidemiology, causes, and risk factors"</a>.)</p><p class="headingAnchor" id="H19329539"><span class="h2">High-risk occupations</span><span class="headingEndMark"> — </span>The risk of OR in various occupations was assessed in a study that analyzed 1244 incident cases of OR reported from 1986 to 1991 to the Finnish Register of Occupational Diseases [<a href="#rid21">21</a>]. The greatest risk of OR was among furriers, followed by bakers, livestock breeders, food processing workers, veterinarians, farmers, assemblers of electrical, electronic, and telecommunication products, and boat builders. A later study identified medical workers and pharmacy professionals as additional high-risk groups [<a href="#rid22">22</a>]. In contrast, office workers are at low-risk for OR.</p><p>Laboratory employees working with small animals are one of the highest risk groups in the United States, the United Kingdom, and several European countries [<a href="#rid23">23</a>]. Studies have reported that the prevalence of laboratory animal allergy is 10 to 23 percent [<a href="#rid23">23-25</a>] and that the incidence rate is 1.56 per 1000 workers for OA and 2.54 per 1000 workers for OR [<a href="#rid26">26</a>]. A study suggests that indirect exposure may be as risky for sensitization to laboratory animal antigens as direct exposure. Also, even nonsensitized workers may still be at risk for OR, as aerosolized endotoxin from animals has been shown to cause symptoms [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>OR can arise from several different mechanisms. A review of nasal physiology is important in understanding the mechanisms responsible for OR.</p><p class="headingAnchor" id="H7"><span class="h2">Nasal physiology</span><span class="headingEndMark"> — </span>The nasal mucus membrane can respond to noxious stimuli in various ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Congestion resulting from vasodilatation, increased vascular permeability, and sinusoidal pooling in the vascular beds draining the sinus tissues</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus and sneezing due to sensory nerve stimulation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Production of secretions due to glandular stimulation and increased vascular permeability</p><p></p><p>Nasal challenge has provided an excellent model for quantifying responses and for obtaining insights into nasal physiology. The nose can be challenged with allergens, mediators, or irritants. The response can be quantified by symptom scores, nasal airway resistance, and the study of secretions. (See <a class="local">'Direct nasal challenge'</a> below.)</p><p>Specific measurements of secretions include amount, composition, and content of various regulatory molecules, proteins, enzymes, and cells. Some of the components of nasal secretions that have been studied are prostaglandin D<sub>2</sub> (PGD<sub>2</sub>), toxoid-antitoxoid mixture esterase (TAMe), kinins, albumin, immunoglobulins, cytokines, lactoferrin, tryptase, major basic protein, cell adhesion molecules, endothelial growth factors, and acute-phase reactant proteins.</p><p>An early response is universal in atopic individuals following nasal challenge with an allergen to which the patient is sensitized. Within minutes, subjects develop sneezing, nasal congestion, and an increase in nasal secretions. This early response is largely mast cell mediated, while the late response involves other cell types. The delayed cellular influx, which can be demonstrated in nasal lavage fluid four to six hours after challenge, is similar to the late changes seen in the lung after bronchial challenge. Total cells increase, as do epithelial cells, eosinophils, neutrophils, and mononuclear cells. Nasal lavage fluid obtained within 11 hours of the challenge shows increased levels of histamine, TAMe, PGD<sub>2</sub>, and kinins [<a href="#rid27">27</a>]. Just as in the lung, the late-phase reaction in the nose is associated with a heightened response to allergen and to nonspecific agents, such as histamine [<a href="#rid28">28</a>].</p><p>There is also evidence to suggest that the size of the agent may influence the type of immunologic response elicited. Individuals exposed to high molecular weight (HMW) agents were found to have higher levels of the acute-phase reactant proteins fibrinogen and haptoglobin, as well as higher levels of vascular cell adhesion molecule (VCAM), vascular endothelial growth factor (VEGF), and vitamin D (VDBP) in nasal lavage compared with individuals exposed to low molecular weight (LMW) agents [<a href="#rid29">29</a>].</p><p>Additionally, the neurogenic system plays a role in the development of rhinitis symptoms via release of various neuropeptides including substance P and neurokinin A and B. These neuropeptides can directly activate mucus-producing cells (leading to rhinorrhea), endothelial cells (leading to nasal congestion), and mast cells [<a href="#rid30">30,31</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Classification and mechanisms</span><span class="headingEndMark"> — </span>A classification system for OR has been proposed  (<a class="graphic graphic_table graphicRef72564" href="/z/d/graphic/72564.html" rel="external">table 1</a>) [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H484824182"><span class="h3">Immunologic occupational rhinitis</span><span class="headingEndMark"> — </span>Immunologic or sensitizer-induced OR is primarily mediated by specific immunoglobulin (Ig)E production, with resultant early and late nasal secretions. HMW allergens or LMW allergens bound to proteins can elicit an allergic response  (<a class="graphic graphic_table graphicRef66185" href="/z/d/graphic/66185.html" rel="external">table 2</a>). The immunologic mechanisms by which LMW agents cause airway sensitization are largely unclear. Many LMW agents may not be immunogenic by themselves but are known to be excellent haptens and can combine with other tissue proteins, such as human serum albumin, in the respiratory tract. The resultant hapten-protein conjugate acts as a potent immunogen [<a href="#rid33">33</a>]. These mechanisms are identical to those underlying immunologic forms of occupational asthma (OA). (See  <a class="medical medical_review" href="/z/d/html/538.html" rel="external">"Occupational asthma: Pathogenesis"</a>.)</p><p>Examples of substances known to cause immunologic OR include rodent allergens (laboratory workers), latex (health care workers), guar gum (carpet workers), and <a class="drug drug_general" data-topicid="9834" href="/z/d/drug information/9834.html" rel="external">psyllium</a> used in laxatives (nurses)  (<a class="graphic graphic_table graphicRef72564" href="/z/d/graphic/72564.html" rel="external">table 1</a>).</p><p>Immunologic OR is often associated with ocular symptoms, such as ocular itching, excessive tearing, redness, and swelling of the eyelids. (See  <a class="medical medical_review" href="/z/d/html/5547.html" rel="external">"Allergic conjunctivitis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H3997813891"><span class="h3">Nonimmunologic occupational rhinitis</span><span class="headingEndMark"> — </span>Nonimmunologic OR is caused by nonimmunological and nonspecific mechanisms. Subtypes include irritant-induced, corrosive, and annoyance OR.</p><p class="headingAnchor" id="H10"><span class="h4">Irritant-induced rhinitis</span><span class="headingEndMark"> — </span>Irritant-induced rhinitis (IIR) is defined as inflammation of the nasal mucosa that has no immunologic or allergic basis. Exposure to substances, such as cigarette smoke, formalin, and <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a>, results in the release of substance P, a sensory transmitter that in turn triggers a neurogenic inflammatory response. This type of OR is seen in workers in enclosed environments exposed to materials, such as paints, talc, coal dust, air pollutants, or cold air  (<a class="graphic graphic_table graphicRef72564" href="/z/d/graphic/72564.html" rel="external">table 1</a>). Cleaners and janitors can develop irritational OR in response to cleaning products [<a href="#rid34">34,35</a>].</p><p class="headingAnchor" id="H11"><span class="h4">Corrosive</span><span class="headingEndMark"> — </span>Corrosive OR results from exposure to a high concentration of irritating and soluble chemical gases, which can cause sufficient nasal inflammation that the mucosa can break down and ulcerate, similar to a chemical burn. Common culprits include substances with high water solubility and chemical reactivity, such as chlorine, sulphur dioxide, ammonia, and formaldehyde  (<a class="graphic graphic_table graphicRef72564" href="/z/d/graphic/72564.html" rel="external">table 1</a>) [<a href="#rid36">36</a>]. Corrosive OR can lead to permanent changes in physiologic functions of the nose, such as loss of olfaction. The entity "reactive upper-airways dysfunction syndrome" (RUDS) has been described after a single exposure to strong chemicals and is modeled on reactive airways dysfunction syndrome (RADS) [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/536.html" rel="external">"Irritant-induced asthma"</a>.)</p><p class="headingAnchor" id="H202609058"><span class="h4">Annoyance</span><span class="headingEndMark"> — </span>Annoyance OR is a purely subjective condition that occurs in individuals with a heightened olfactory awareness to substances, such as department store or supermarket employees who become symptomatic upon exposure to perfumes or detergents, respectively. Nasal mucosal inflammation is not evident. Annoyance OR is a negative psychologic state, at times in conjunction with transient physical symptoms related to the perception of offensive air quality due to strong odors. The likelihood of developing annoyance reactions is increased by nasal polyposis, sinusitis, tobacco use, and overuse of over-the-counter nasal decongestants or illicit drugs [<a href="#rid19">19</a>]. The mechanism has not been demonstrated.</p><p class="headingAnchor" id="H13"><span class="h2">Levels of exposure</span><span class="headingEndMark"> — </span>Patients with OR are not necessarily exposed to levels of the causative agent that are considered unsafe by industry standards [<a href="#rid37">37</a>]. A study of customs officers found that changes in nasal cytology were evident in those exposed to diesel exhaust emissions, although the levels were well within the permitted range [<a href="#rid38">38</a>].</p><p>For patients with immunologic/allergic OR, even minute amounts of allergen can trigger symptoms in susceptible patients.</p><p class="headingAnchor" id="H14"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H15"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>The symptoms of OR are nasal congestion, sneezing, nasal pruritus, and/or increased nasal secretions in association with exposure to the workplace. Since OR can be associated with a late reaction, symptoms may not appear until several hours after leaving the workplace. Late-onset symptoms in the absence of immediate symptoms is uncommon, although it has been reported [<a href="#rid39">39</a>]. In some forms of OR, there may be associated ocular or pulmonary signs and symptoms.</p><p class="headingAnchor" id="H16"><span class="h2">Timing of symptom onset</span><span class="headingEndMark"> — </span>The symptoms of OR usually appear within the first one to three years of employment [<a href="#rid16">16,37,40,41</a>]. However, the latency period between exposure and symptom onset may differ among occupations.</p><p class="headingAnchor" id="H17"><span class="h1">DIAGNOSTIC ASSESSMENT</span><span class="headingEndMark"> — </span>Occupational rhinitis remains a diagnostic challenge. In the community, the diagnosis of OR is most often based upon correlative history, suggestive clinical signs and symptoms, and (if feasible) observation of the patient's symptoms during a site visit. Direct nasal challenge may establish a definite diagnosis but is often not necessary and may be difficult to perform appropriately outside of a research or specialized testing center [<a href="#rid4">4</a>].</p><p>The following steps are suggested in the evaluation of OR [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>History and physical examination</p><p class="bulletIndent1"><span class="glyph">●</span>Confirmation of work relatedness</p><p class="bulletIndent1"><span class="glyph">●</span>Identification and confirmation of the suspected cause</p><p></p><p class="headingAnchor" id="H18"><span class="h2">History</span><span class="headingEndMark"> — </span>A comprehensive occupational history should contain questions pertaining to the following [<a href="#rid19">19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Onset of symptoms at work</p><p class="bulletIndent1"><span class="glyph">●</span>Improvement on weekends or vacations</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrence of symptoms on reexposure</p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to cold air, ozone (eg, pulp mill and bleachery workers), pollution, tobacco smoke, animals, and dusts</p><p class="bulletIndent1"><span class="glyph">●</span>Similar symptoms in coworkers</p><p class="bulletIndent1"><span class="glyph">●</span>Duration working at current job</p><p class="bulletIndent1"><span class="glyph">●</span>Adequacy of ventilation</p><p class="bulletIndent1"><span class="glyph">●</span>Compliance with wearing gloves, masks, and protective clothing</p><p class="bulletIndent1"><span class="glyph">●</span>History of accidents or spills</p><p class="bulletIndent1"><span class="glyph">●</span>Safety monitoring</p><p class="bulletIndent1"><span class="glyph">●</span>Review of material safety data sheets</p><p class="bulletIndent1"><span class="glyph">●</span>Personal or family history of atopy</p><p class="bulletIndent1"><span class="glyph">●</span>Coexisting symptoms, such as bronchitis, dermatitis, conjunctivitis, or anosmia</p><p class="bulletIndent1"><span class="glyph">●</span>Tobacco use</p><p class="bulletIndent1"><span class="glyph">●</span>Previous employment</p><p class="bulletIndent1"><span class="glyph">●</span>Intranasal medications (eg, topical decongestants) or illicit drugs (eg, cocaine)</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Physical examination during the time of active rhinitis reveals swollen nasal turbinates and evidence of increased secretions. Nasal findings may be minimal in patients with annoyance OR, whereas corrosive OR may reveal ulcerated and hemorrhagic mucosa [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Confirmation of work relatedness</span><span class="headingEndMark"> — </span>Ideally this is accomplished through a site visit, which can provide the clinician with an opportunity to confirm and add to the previously obtained history by observing the patient performing usual job-related tasks. The site visit is also critical for determining if any changes can be made in the work environment to reduce the patient's ongoing exposure.</p><p>In the United States, the Occupational Safety and Health Administration (OSHA) requires employers to keep on-site records detailing the ingredients and possible health effects of materials and substances to which workers are exposed. This information is available in material safety data sheets, which should be reviewed during the site visit. These sheets can be helpful in establishing a causal agent in OR.</p><p>A toxicologist can be consulted to sample air quality if there is a question of inadequate ventilation. However, patients may develop OR (especially allergic OR) from exposure to "safe" amounts of agents. (See <a class="local">'Levels of exposure'</a> above.)</p><p>However, the feasibility of site visits limits their utility. As such, at some centers, the patient is given a diary and instructed to record symptoms several times daily during the work week, on weekends, and during any prolonged absences from the workplace, providing a purely subjective measurement.</p><p class="headingAnchor" id="H463464492"><span class="h2">Identification and confirmation of the suspected cause</span></p><p class="headingAnchor" id="H22"><span class="h3">Testing for allergen-specific IgE</span><span class="headingEndMark"> — </span>Allergy skin testing and in vitro immunoglobulin (Ig)E immunoassays (commonly called ImmunoCAP testing) are methods for detecting allergen-specific IgE. These tests document sensitization to the allergen (ie, the presence of allergen-specific IgE), although not all sensitized patients develop symptoms upon exposure. Thus, direct nasal challenge remains the gold standard for the diagnosis of OR.</p><p>Allergy skin testing is considered a safe procedure, although there is some risk for a generalized allergic reaction (ie, anaphylaxis) in highly sensitive patients. Therefore, skin testing should be performed by allergy specialists who have training in the rapid recognition and treatment of possible reactions. In contrast, IgE immunoassays can be ordered by any clinician, although this form of testing may be less sensitive than skin testing. (See  <a class="medical medical_review" href="/z/d/html/5541.html" rel="external">"Overview of skin testing for IgE-mediated allergic disease"</a> and  <a class="medical medical_review" href="/z/d/html/7525.html" rel="external">"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis"</a>.)</p><p>Testing for allergen-specific IgE is appropriate if both of the following are true:</p><p class="bulletIndent1"><span class="glyph">●</span>The OR is believed to be due to an IgE-mediated mechanism (ie, immunologic OR).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a validated testing extract available for the allergen in question, such as animal danders [<a href="#rid42">42</a>], dust mite, latex (in some countries), or mold. Unfortunately, approved extracts do not exist for many other occupational allergens (especially for low molecular weight agents), and commercially available extracts may be variable in allergen content [<a href="#rid43">43</a>].</p><p></p><p>If a validated extract is not available, then testing with improvised solutions of the suspect allergen is generally not recommended, because irritating substances can cause false-positive results. In addition, false-negative results may occur with low molecular weight allergens, which may need to be conjugated with serum albumin to elicit a positive response [<a href="#rid19">19</a>].</p><p>In contrast, skin testing to common aeroallergens may provide useful information about the general atopic status of the patient, as patients with allergic rhinitis to inhaled allergens are at increased risk for OR. (See <a class="local">'Risk factors'</a> above.)</p><p class="headingAnchor" id="H24"><span class="h2">Direct nasal challenge</span><span class="headingEndMark"> — </span>Direct nasal challenge, also called nasal provocation test, is the gold standard for the diagnosis of OR. It can be performed either at the workplace or under controlled circumstances in the office or laboratory. Responses may be quantified either by symptom score or by rhinomanometry, a technique that measures changes in nasal airway resistance. As mentioned previously, these techniques require special equipment and training and are not practical for most community clinicians or allergy specialists.</p><p>A position paper published by the European Academy of Allergy and Clinical Immunology (EAACI) suggests that workplace challenges be considered in the following settings [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>No sensitizing agent has been firmly identified at work</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple potentially sensitizing agents are present at the workplace</p><p class="bulletIndent1"><span class="glyph">●</span>Conditions of exposure at work cannot be duplicated in the laboratory</p><p class="bulletIndent1"><span class="glyph">●</span>Nasal provocation tests in the laboratory are not feasible</p><p></p><p>During the challenge, the worker performs the usual tasks and nasal response is gauged before, during, and after a typical shift. Patients act as their own controls by comparing workday symptoms to non-workday symptoms. This may be done several times to ascertain sufficient reproducibility. Tools for assessing the severity of allergic rhinitis are available online [<a href="#rid44">44</a>].</p><p>A laboratory nasal allergen challenge would also be useful in cases of putative IgE-mediated mechanism when skin or blood testing for allergen-specific IgE is equivocal and workplace challenges are not possible. Again, this is most applicable to research settings.</p><p class="headingAnchor" id="H25"><span class="h3">Rhinomanometry techniques</span><span class="headingEndMark"> — </span>There are three common rhinomanometry techniques: anterior, posterior, and acoustic.</p><p class="bulletIndent1"><span class="glyph">●</span>Anterior rhinomanometry calculates nasal airway resistance from the relationship between flow rate and pressure. Commercially available anterior rhinomanometers measure airflow through one nostril by means of a closely fitting facemask, whereas the other nostril is sealed with a small tube to measure nasopharyngeal pressure. The technique is easy to perform, requires little patient cooperation, and is especially convenient for nasal provocation. The disadvantages include distortion of the nasal valves by the probe, reflex changes resulting from tactile sensations, and sensitivity of the measurement to nasal cycling (ie, a normal phenomenon in which nasal turbinates on alternate sides of the nose swell at intervals of two to five hours) [<a href="#rid45">45,46</a>]. Normal nasal function and reflexes are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7535.html" rel="external">"Etiologies of nasal obstruction: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/7533.html" rel="external">"An overview of rhinitis", section on 'Normal nasal reflexes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Posterior rhinomanometry employs a facemask fitted with a pneumotachometer and monitors airflow through both nostrils simultaneously, as well as anterior nasal pressure. Posterior rhinomanometry avoids the disadvantages of artifacts from nasal instrumentation and nasal cycling, although the equipment is expensive and the procedure is difficult to perform on some patients. Approximately 20 percent of healthy individuals do not have sufficient palatal control to permit accurate pressure flow recordings to be obtained [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acoustic rhinomanometry is a simple, easily reproducible, and less invasive procedure in which sound waves are introduced into the nasal cavity and a computer quantifies the reflected waves [<a href="#rid47">47,48</a>]. Of the three techniques, acoustic rhinomanometry is the most practical and least invasive.</p><p></p><p class="headingAnchor" id="H26"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of OR includes avoidance of the causative agent and pharmacotherapy with intranasal glucocorticoid sprays and/or nonsedating antihistamines. In the United States, OR is not a reportable condition, in contrast with occupational asthma (OA).</p><p>Patients with severe symptoms that are not relieved by the measures described below, combined with pharmacotherapy, may need to consider a change in employment.</p><p class="headingAnchor" id="H27"><span class="h2">Avoidance</span><span class="headingEndMark"> — </span>The management of OR begins with eliminating or minimizing exposure to the causative agent. In our experience, effective avoidance usually results in resolution of symptoms. In prospective studies, workers with OR who changed jobs or retired reported significant improvement in symptoms and quality of life, even in those with preexisting rhinitis [<a href="#rid49">49,50</a>].</p><p>Exposure may be reduced in a number of ways, including [<a href="#rid51">51,52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Substitution of the causative agent with an alternative material</p><p class="bulletIndent1"><span class="glyph">●</span>Consistent use of protective equipment, such as a mask</p><p class="bulletIndent1"><span class="glyph">●</span>Improved ventilation or containment of the causative agent</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced exposure times to the causative agent</p><p></p><p>Following these measures could well make it possible for the worker to maintain employment.</p><p>The natural history of OR has not been extensively studied, nor has the impact of ongoing exposure to causative agents. There is a lack of evidence that OR progresses to more extensive respiratory involvement. However, it is not known if some patients develop rhinitis initially in response to occupational agents but then become sensitive to other triggers and develop persistent symptoms despite avoidance of the initial culprit.</p><p class="headingAnchor" id="H28"><span class="h3">Corrosive occupational rhinitis</span><span class="headingEndMark"> — </span>Avoidance is the sole treatment for corrosive OR, and the worker must be adequately protected from corrosive materials. Medications should not be used to reduce the clinical manifestations of this condition, because the patient's awareness of symptoms is important to avoid mucosal injury. Recovery rates and sequelae from this form of nasal injury have not been reported.</p><p class="headingAnchor" id="H29"><span class="h2">Pharmacotherapy</span><span class="headingEndMark"> — </span>Pharmacotherapy can be helpful for annoyance, irritational, and allergic forms of OR, although there are no randomized trials or even large series evaluating pharmacotherapy for OR specifically. Recommendations for management are extrapolated from the literature on allergic rhinitis and in our experience are equally helpful for allergic OR. However, the response of annoyance and irritational OR to these therapies has not been reported.</p><p>Patients should be counseled that medications are only palliative rather than curative, and efforts to reduce exposure are primary. Ideally, pharmacotherapy should be continued until the patient can control symptoms by avoiding exposure to the offending agent.</p><p class="headingAnchor" id="H30"><span class="h3">Intranasal glucocorticoids</span><span class="headingEndMark"> — </span>Topical glucocorticoid nasal sprays are most effective when taken regularly, although they can be used on an as-needed basis. Preparations with once-daily dosing are convenient and can help optimize compliance. These include <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide, <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a>, <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a> propionate, <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">mometasone</a> furoate, fluticasone furoate, <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">beclomethasone</a> dipropionate, and <a class="drug drug_general" data-topicid="8537" href="/z/d/drug information/8537.html" rel="external">ciclesonide</a>  (<a class="graphic graphic_table graphicRef55833" href="/z/d/graphic/55833.html" rel="external">table 3</a>). Most intranasal glucocorticoids are used at a dose of 1 to 2 sprays in each nostril once or twice per day. The optimal use of these medications is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis"</a>.)</p><p class="headingAnchor" id="H31"><span class="h3">Antihistamines</span><span class="headingEndMark"> — </span>Over-the-counter or prescription nonsedating antihistamines are also helpful for managing annoyance, irritant-induced, and immunologic OR. Antihistamines are less effective for allergic rhinitis than topical glucocorticoid nasal sprays, although some patients prefer oral medications. When the patient's symptoms are episodic and predictable, prophylactic use before exposure is usually sufficient. When symptoms are frequent or unpredictable, regular use of an antihistamine may be necessary.</p><p>We avoid sedating first-generation antihistamines (eg, <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, <a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">chlorpheniramine</a>, astemizole, and others), since the goal of treatment is to increase alertness and job performance. The second-generation, less sedating antihistamines include <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">loratadine</a> (10 mg once daily), <a class="drug drug_general" data-topicid="8472" href="/z/d/drug information/8472.html" rel="external">desloratadine</a> (5 mg once daily), <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">fexofenadine</a> (180 mg once daily), <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a> (10 mg once daily), and <a class="drug drug_general" data-topicid="9443" href="/z/d/drug information/9443.html" rel="external">levocetirizine</a> (2.5 or 5 mg once daily). The choice of agent is often based on trial and error, side effect profile, cost to the patient, and availability. (See  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis"</a>.)</p><p>Topical antihistamine nasal sprays may also be helpful. These include <a class="drug drug_general" data-topicid="8798" href="/z/d/drug information/8798.html" rel="external">azelastine</a> and <a class="drug drug_general" data-topicid="10177" href="/z/d/drug information/10177.html" rel="external">olopatadine</a>, both of which have a rapid onset of action (less than 15 minutes) and can be administered "on demand" for patients with episodic and unpredictable exposures. (See  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis"</a>.)</p><p class="headingAnchor" id="H32"><span class="h3">Other therapies</span><span class="headingEndMark"> — </span>Other adjunctive therapies may be helpful to some patients [<a href="#rid53">53</a>]. Although these interventions have not been studied specifically for OR, they have been shown to help various other types of rhinitis (see  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">Ipratropium</a> nasal spray</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leukotriene-modifying drugs, such as <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>, or <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nasal irrigation with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, performed when the patient is done with work for the day (see  <a class="medical medical_basics" href="/z/d/html/86630.html" rel="external">"Patient education: How to rinse out your nose with salt water (The Basics)"</a>)</p><p></p><p>For patients with accompanying ocular symptoms, ophthalmic solutions of antihistamines/mast cell stabilizers may provide as-needed prophylactic or symptomatic treatment of accompanying conjunctivitis. (See  <a class="medical medical_review" href="/z/d/html/5547.html" rel="external">"Allergic conjunctivitis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H11822358"><span class="h2">Immunotherapy</span><span class="headingEndMark"> — </span>Allergen immunotherapy is not recommended for the majority of patients with OR for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Allergen immunotherapy has no role in the management of rhinitis caused by irritative or corrosive substances.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapeutic extracts have not been produced for most occupational allergens and, in some cases, may not be safe.</p><p></p><p>In cases where appropriate allergens are available, such as veterinarians with OR caused by cat or dog allergens, the efficacy of allergen immunotherapy in the setting of ongoing intense exposure has not been evaluated. However, it is the authors' anecdotal experience that cat or dog immunotherapy in small animal veterinarians is useful, particularly if the patient also limits non-work-related exposure by not keeping such pets in the home.</p><p>Preliminary studies have described immunotherapy with certain occupational allergens that are not easily avoided (eg, natural rubber latex for health care workers) [<a href="#rid54">54-56</a>], although the safety and efficacy of this approach require further study. (See  <a class="medical medical_review" href="/z/d/html/5554.html" rel="external">"Latex allergy: Management", section on 'Immunotherapy'</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Many patients appear to have stable OR over a period of years. This is in contrast with occupational asthma (OA), which usually worsens with continued exposure. Therefore, we advise our patients to protect themselves as much as possible from ongoing exposure and to consider changing work environments if their symptoms appear to be worsening despite avoidance measures. A study among OR patients showed continuous occupational exposure decreased quality-of-life years after the diagnosis. The authors concluded that to restore the well-being of patients with OR, medication alone was not sufficient. Reduction or cessation of exposure was necessary. For patients with OR who were no longer exposed to the causative agent, quality of life was similar to healthy controls [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H83552520"><span class="h2">Risk of developing occupational asthma</span><span class="headingEndMark"> — </span>Several longitudinal cohort studies have implicated OR as a risk factor for development of occupational asthma (OA) [<a href="#rid4">4,7,8,41</a>]. Additionally, OA is more often associated with OR when attributed to high molecular weight allergens than when attributed to low molecular weight allergens (72 versus 52 percent, respectively) [<a href="#rid6">6,58</a>]. Thus, the relationship between OR and OA may depend in part on the causative allergen. When asked by patients about the risk of developing asthma, we explain that it is possible that OR will progress to OA in some individuals, but the risk is not well-defined. It may be higher with the high molecular weight allergens, and we advise greater caution for patients who have OR to these allergens.</p><p class="headingAnchor" id="H34"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>In 2011, the European Academy of Allergy and Clinical Immunology (EAACI) released a position paper regarding the prevention of work-related respiratory allergies among pre-apprentices or apprentices and young workers [<a href="#rid59">59</a>]. Consensus suggestions for prevention strategies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Information campaigns and educational tools so that workers may develop an understanding of the risks and preventative measures associated with occupational exposures</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Environmental control as a cornerstone of prevention</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preemployment health assessment and advice, with medical surveillance prioritized during the first two to three working years</p><p></p><p>Screening applicants for jobs in which there is a risk of workplace sensitization had previously been proposed as a means of preventing allergic OR. A study of 110 laboratory animal workers reported that the combination of atopy and total immunoglobulin (Ig)E levels ≥100 international units/mL could be used as a preemployment screen to predict which workers would develop occupational allergy. The study estimated that such screening might be able to reduce occupational sensitization by up to 45 to 50 percent, with less than 10 percent false-positive predictions [<a href="#rid60">60</a>]. However, the social, financial, and legal implications of such screening necessitate careful consideration, and we believe that these measures require further study before they are applied clinically.</p><p>Nonatopic individuals can also develop OR, and screening for atopy does not identify at-risk subjects in this group. In a study of applicants for laboratory jobs involving rat exposure, applicants were screened with a panel of common inhalant allergens to identify atopic individuals [<a href="#rid61">61</a>]. Of the 41 workers who were initially atopic by history and skin testing, 23 percent went on to develop OR. However, a significant number of the workers who developed rat allergies were not initially atopic.</p><p>In 2012, the Joint Task Force on Practice Parameters published a practice parameter on environmental assessment and reduction of rodent exposure, which addressed the prevention of occupational allergy in animal workers handling rodents [<a href="#rid62">62</a>]. It stated that testing for rodent sensitization (using immunoassays for rodent-specific IgE or skin prick testing) should be considered for at least the first three years of exposure and that extra preventive measures be offered to individuals with high risk for developing allergy (ie, those with sensitization, underlying atopy, or high levels of exposure).</p><p>A general approach to prevention, which applies to all workers and all forms of OR, is to institute environmental control measures proactively. It is important to recognize and identify potential sources of offending allergens and then minimize the worker's exposure to them as much as possible. This may be as simple as providing adequate ventilation.</p><p>An example of the effectiveness of environmental control measures was seen in the detergent industry. The <em>Bacillus subtilis</em> enzyme added to household detergents caused a significant amount of upper and lower respiratory tract allergy in workers. By instituting a number of precautions during the production process, the incidence of occupational respiratory disease was greatly decreased [<a href="#rid63">63</a>]. These precautions included enclosing previously open operations, supplying heavily exposed workers with full-coverage protective suits with an air supply, providing disposable gloves and uniforms, providing masks with cartridge filters to workers with low exposure, monitoring the air by measuring enzyme concentrations, and performing spot checks on workers. These spot checks consisted of a history and physical examination, chest radiographs, pulmonary function testing, skin testing, and serologic testing.</p><p class="headingAnchor" id="H3563039813"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109564.html" rel="external">"Society guideline links: Rhinitis"</a>.)</p><p class="headingAnchor" id="H35"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>– Occupational rhinitis (OR) has been defined as episodic, work-related occurrence of sneezing, nasal discharge, nasal pruritus, and/or nasal obstruction. OR often coexists with occupational asthma (OA), although significant numbers of patients develop just one of these conditions. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– The overall prevalence of OR is unknown, and accurate identification is complicated by the high prevalence of rhinitis in general. High-risk professions include laboratory workers, food processing workers, veterinarians, farmers and livestock workers, and assemblers of electronic and telecommunication products. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– OR may develop in response to respiratory irritants, corrosive gases, or allergens. It may be immunoglobulin (Ig)E mediated or non-IgE mediated. A classification system delineates four subtypes: annoyance, irritational, corrosive, and immunologic/allergic  (<a class="graphic graphic_table graphicRef72564" href="/z/d/graphic/72564.html" rel="external">table 1</a>). (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– The symptoms of OR are nasal congestion, sneezing, nasal pruritus, and/or increased nasal secretions in association with exposure to the workplace. Symptoms can develop within minutes to several hours after exposure. There may be associated ocular or pulmonary signs and symptoms. OR usually develops within the first few years of employment. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation </strong>– The evaluation of a patient suspected of having OR includes a detailed occupational history, physical examination, verification of work-relatedness, and, in cases of suspected immunologic OR, skin testing or in vitro testing to common inhalant allergens. In a few situations, commercial extracts of occupational allergens are also available for testing, although we do not recommend testing with improvised extracts. (See <a class="local">'Diagnostic assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis is usually made clinically, although, for research purposes, symptoms should be elicited and confirmed by direct nasal challenge. (See <a class="local">'Diagnostic assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitigate exposure </strong>– The primary therapy for all forms of OR is reduction or elimination of the patient's exposure to the causative agent. This is the only appropriate intervention for corrosive OR. (See <a class="local">'Avoidance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacotherapy </strong>– Pharmacotherapy may be useful while avoidance measures are being put in place or it may be needed on an ongoing basis. Medications may be used as needed for episodic and predictable exposures or daily for regular or unpredictable exposures. (See <a class="local">'Pharmacotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend that patients with immunologic OR be treated with the same medications used for nonoccupational allergic rhinitis (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Pharmacotherapy is primarily based upon intranasal glucocorticoid sprays, nonsedating antihistamines, or both. (See  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with annoyance and irritant-induced forms of OR, we suggest therapeutic trials of the same agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Pharmacotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis with ongoing exposure </strong>– In patients whose symptoms are controlled but who cannot eliminate exposure, we suggest against advising them that they must leave their jobs (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, there may be a greater association between OR and OA in patients exposed to high molecular weight sensitizing agents  (<a class="graphic graphic_table graphicRef66185" href="/z/d/graphic/66185.html" rel="external">table 2</a>). Accordingly, we are more cautious in our approach to these patients, screening for asthma symptoms and generally advising against continued exposure (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– The development of screening parameters to identify those individuals at highest risk for allergic OR is an area of active investigation, but validated methods for clinical application are still lacking. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H1221760947"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jennifer Gentner, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Moscato G, Vandenplas O, Van Wijk RG, et al. EAACI position paper on occupational rhinitis. Respir Res 2009; 10:16.</a></li><li><a class="nounderline abstract_t">Hox V, Steelant B, Fokkens W, et al. Occupational upper airway disease: how work affects the nose. Allergy 2014; 69:282.</a></li><li><a class="nounderline abstract_t">Siracusa A, Folletti I, Moscato G. Non-IgE-mediated and irritant-induced work-related rhinitis. Curr Opin Allergy Clin Immunol 2013; 13:159.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Hox V, Bernstein D. Occupational Rhinitis. J Allergy Clin Immunol Pract 2020; 8:3311.</a></li><li><a class="nounderline abstract_t">Stevens WW, Grammer LC 3rd. Occupational rhinitis: an update. Curr Allergy Asthma Rep 2015; 15:487.</a></li><li><a class="nounderline abstract_t">Ameille J, Hamelin K, Andujar P, et al. Occupational asthma and occupational rhinitis: the united airways disease model revisited. Occup Environ Med 2013; 70:471.</a></li><li><a class="nounderline abstract_t">Elliott L, Heederik D, Marshall S, et al. Progression of self-reported symptoms in laboratory animal allergy. J Allergy Clin Immunol 2005; 116:127.</a></li><li><a class="nounderline abstract_t">Karjalainen A, Martikainen R, Klaukka T, et al. Risk of asthma among Finnish patients with occupational rhinitis. Chest 2003; 123:283.</a></li><li><a class="nounderline abstract_t">Slavin RG. Occupational rhinitis. Immunol Allergy Clin North Am 1992; 12:769.</a></li><li><a class="nounderline abstract_t">Slavin RG. Update on occupational rhinitis and asthma. Allergy Asthma Proc 2010; 31:437.</a></li><li><a class="nounderline abstract_t">Siracusa A, Desrosiers M, Marabini A. Epidemiology of occupational rhinitis: prevalence, aetiology and determinants. Clin Exp Allergy 2000; 30:1519.</a></li><li><a class="nounderline abstract_t">Garnier R, Villa A, Chataigner D. [Occupational rhinitis]. Rev Mal Respir 2007; 24:205.</a></li><li><a class="nounderline abstract_t">Ruoppi P, Koistinen T, Susitaival P, et al. Frequency of allergic rhinitis to laboratory animals in university employees as confirmed by chamber challenges. Allergy 2004; 59:295.</a></li><li><a class="nounderline abstract_t">Chloros D, Sichletidis L, Kyriazis G, et al. Respiratory effects in workers processing dried tobacco leaves. Allergol Immunopathol (Madr) 2004; 32:344.</a></li><li><a class="nounderline abstract_t">Le Moual N, Kauffmann F, Eisen EA, Kennedy SM. The healthy worker effect in asthma: work may cause asthma, but asthma may also influence work. Am J Respir Crit Care Med 2008; 177:4.</a></li><li><a class="nounderline abstract_t">Walusiak J, Hanke W, Górski P, Pałczyński C. Respiratory allergy in apprentice bakers: do occupational allergies follow the allergic march? Allergy 2004; 59:442.</a></li><li><a class="nounderline abstract_t">Rodier F, Gautrin D, Ghezzo H, Malo JL. Incidence of occupational rhinoconjunctivitis and risk factors in animal-health apprentices. J Allergy Clin Immunol 2003; 112:1105.</a></li><li><a class="nounderline abstract_t">Jang JH, Kim DW, Kim SW, et al. Allergic rhinitis in laboratory animal workers and its risk factors. Ann Allergy Asthma Immunol 2009; 102:373.</a></li><li><a class="nounderline abstract_t">Puchner TC, Fink JN. Occupational Rhinitis. Immunol Allergy Clin North Am 2000; 20:303.</a></li><li><a class="nounderline abstract_t">Gautrin D, Ghezzo H, Infante-Rivard C, Malo JL. Incidence and host determinants of work-related rhinoconjunctivitis in apprentice pastry-makers. Allergy 2002; 57:913.</a></li><li><a class="nounderline abstract_t">Hytönen M, Kanerva L, Malmberg H, et al. The risk of occupational rhinitis. Int Arch Occup Environ Health 1997; 69:487.</a></li><li><a class="nounderline abstract_t">Moscato G, Siracusa A. Rhinitis guidelines and implications for occupational rhinitis. Curr Opin Allergy Clin Immunol 2009; 9:110.</a></li><li><a class="nounderline abstract_t">Lutsky II, Neuman I. Laboratory animal dander allergy: I. An occupational disease. Ann Allergy 1975; 35:201.</a></li><li><a class="nounderline abstract_t">Aoyama K, Ueda A, Manda F, et al. Allergy to laboratory animals: an epidemiological study. Br J Ind Med 1992; 49:41.</a></li><li><a class="nounderline abstract_t">Hollander A, Doekes G, Heederik D. Cat and dog allergy and total IgE as risk factors of laboratory animal allergy. J Allergy Clin Immunol 1996; 98:545.</a></li><li><a class="nounderline abstract_t">Elliott L, Heederik D, Marshall S, et al. Incidence of allergy and allergy symptoms among workers exposed to laboratory animals. Occup Environ Med 2005; 62:766.</a></li><li><a class="nounderline abstract_t">Naclerio RM, Meier HL, Kagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983; 128:597.</a></li><li><a class="nounderline abstract_t">Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985; 313:65.</a></li><li><a class="nounderline abstract_t">Castano R, Yucesoy B, Johnson VJ, et al. Inflammatory proteins in nasal lavage of workers exposed to occupational agents. Clin Exp Allergy 2017; 47:1566.</a></li><li><a class="nounderline abstract_t">Ronsmans S, Steelant B, Backaert W, et al. Diagnostic approach to occupational rhinitis: the role of nasal provocation tests. Curr Opin Allergy Clin Immunol 2020; 20:122.</a></li><li><a class="nounderline abstract_t">Van Gerven L, Steelant B, Hellings PW. Nasal hyperreactivity in rhinitis: A diagnostic and therapeutic challenge. Allergy 2018; 73:1784.</a></li><li><a class="nounderline abstract_t">Bardana EJ Jr. Occupational asthma and related respiratory disorders. Dis Mon 1995; 41:143.</a></li><li><a class="nounderline abstract_t">Slavin RG. Occupational rhinitis. Ann Allergy Asthma Immunol 2003; 90:2.</a></li><li><a class="nounderline abstract_t">de Fátima Maçãira E, Algranti E, Medina Coeli Mendonça E, Antônio Bussacos M. Rhinitis and asthma symptoms in non-domestic cleaners from the Sao Paulo metropolitan area, Brazil. Occup Environ Med 2007; 64:446.</a></li><li><a class="nounderline abstract_t">Radon K, Gerhardinger U, Schulze A, et al. Occupation and adult onset of rhinitis in the general population. Occup Environ Med 2008; 65:38.</a></li><li><a class="nounderline abstract_t">Hellgren J, Torén K. Nonallergic occupational rhinitis. Clin Allergy Immunol 2007; 19:241.</a></li><li><a class="nounderline abstract_t">Cullinan P, Cook A, Nieuwenhuijsen MJ, et al. Allergen and dust exposure as determinants of work-related symptoms and sensitization in a cohort of flour-exposed workers; a case-control analysis. Ann Occup Hyg 2001; 45:97.</a></li><li><a class="nounderline abstract_t">Glück U, Schütz R, Gebbers JO. Cytopathology of the nasal mucosa in chronic exposure to diesel engine emission: a five-year survey of Swiss customs officers. Environ Health Perspect 2003; 111:925.</a></li><li><a class="nounderline abstract_t">Blainey AD, Graham VA, Phillips MJ, Davies RJ. Respiratory tract reactions to western red cedar. Hum Toxicol 1981; 1:41.</a></li><li><a class="nounderline abstract_t">Cullinan P, Cook A, Gordon S, et al. Allergen exposure, atopy and smoking as determinants of allergy to rats in a cohort of laboratory employees. Eur Respir J 1999; 13:1139.</a></li><li><a class="nounderline abstract_t">Gautrin D, Ghezzo H, Infante-Rivard C, Malo JL. Natural history of sensitization, symptoms and occupational diseases in apprentices exposed to laboratory animals. Eur Respir J 2001; 17:904.</a></li><li><a class="nounderline abstract_t">Sharma HP, Wood RA, Bravo AR, Matsui EC. A comparison of skin prick tests, intradermal skin tests, and specific IgE in the diagnosis of mouse allergy. J Allergy Clin Immunol 2008; 121:933.</a></li><li><a class="nounderline abstract_t">van Kampen V, de Blay F, Folletti I, et al. EAACI position paper: skin prick testing in the diagnosis of occupational type I allergies. Allergy 2013; 68:580.</a></li><li class="breakAll">Practice parameters for assessing the severity of allergic rhinitis have been developed by the Joint Task Force on Practice Parameters, a body representing the American Academy of Allergy, Asthma, and Immunology, and the American College of Allergy, Asthma, and Immunology. http://www.allergyparameters.org/file_depot/0-10000000/30000-40000/30326/folder/73825/2003Rhinitis.pdf#page=1&amp;zoom=auto,9,800 (Accessed on April 26, 2013).</li><li><a class="nounderline abstract_t">Schumacher MJ. Rhinomanometry. J Allergy Clin Immunol 1989; 83:711.</a></li><li><a class="nounderline abstract_t">Baraniuk JN, Kim D. Nasonasal reflexes, the nasal cycle, and sneeze. Curr Allergy Asthma Rep 2007; 7:105.</a></li><li><a class="nounderline abstract_t">Hytonen ML, Sala EL, Malmberg HO, Nordman H. Acoustic rhinomanometry in the diagnosis of occupational rhinitis. Am J Rhinol 1996; 10:393.</a></li><li><a class="nounderline abstract_t">Castano R, Thériault G, Gautrin D, et al. Reproducibility of acoustic rhinometry in the investigation of occupational rhinitis. Am J Rhinol 2007; 21:474.</a></li><li><a class="nounderline abstract_t">Gerth van Wijk R, Patiwael JA, de Jong NW, et al. Occupational rhinitis in bell pepper greenhouse workers: determinants of leaving work and the effects of subsequent allergen avoidance on health-related quality of life. Allergy 2011; 66:903.</a></li><li><a class="nounderline abstract_t">Castano R, Trudeau C, Castellanos L, Malo JL. Prospective outcome assessment of occupational rhinitis after removal from exposure. J Occup Environ Med 2013; 55:579.</a></li><li><a class="nounderline abstract_t">Gautrin D, Desrosiers M, Castano R. Occupational rhinitis. Curr Opin Allergy Clin Immunol 2006; 6:77.</a></li><li><a class="nounderline abstract_t">Hellgren J, Karlsson G, Torén K. The dilemma of occupational rhinitis: management options. Am J Respir Med 2003; 2:333.</a></li><li><a class="nounderline abstract_t">Puchner TC, Fink JN. Occupational Rhinitis. Immunol Allergy Clin North Am 2000; 20:303.</a></li><li><a class="nounderline abstract_t">Sastre J, Fernández-Nieto M, Rico P, et al. Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2003; 111:985.</a></li><li><a class="nounderline abstract_t">Nettis E, Colanardi MC, Soccio AL, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol 2007; 156:674.</a></li><li><a class="nounderline abstract_t">Hansen I, Hörmann K, Klimek L. [Specific immunotherapy in inhalative allergy to rat epithelium]. Laryngorhinootologie 2004; 83:512.</a></li><li><a class="nounderline abstract_t">Airaksinen LK, Luukkonen RA, Lindström I, et al. Long-term exposure and health-related quality of life among patients with occupational rhinitis. J Occup Environ Med 2009; 51:1288.</a></li><li><a class="nounderline abstract_t">Balogun RA, Siracusa A, Shusterman D. Occupational rhinitis and occupational asthma: Association or progression? Am J Ind Med 2018; 61:293.</a></li><li><a class="nounderline abstract_t">Moscato G, Pala G, Boillat MA, et al. EAACI position paper: prevention of work-related respiratory allergies among pre-apprentices or apprentices and young workers. Allergy 2011; 66:1164.</a></li><li><a class="nounderline abstract_t">Krop EJ, Heederik DJ, Lutter R, et al. Associations between pre-employment immunologic and airway mucosal factors and the development of occupational allergy. J Allergy Clin Immunol 2009; 123:694.</a></li><li><a class="nounderline abstract_t">Platts-Mills TA, Longbottom J, Edwards J, et al. Occupational asthma and rhinitis related to laboratory rats: serum IgG and IgE antibodies to the rat urinary allergen. J Allergy Clin Immunol 1987; 79:505.</a></li><li><a class="nounderline abstract_t">Phipatanakul W, Matsui E, Portnoy J, et al. Environmental assessment and exposure reduction of rodents: a practice parameter. Ann Allergy Asthma Immunol 2012; 109:375.</a></li><li><a class="nounderline abstract_t">Slavin RG, Lewis CR. Sensitivity to enzyme additives in laundry detergent workers. J Allergy Clin Immunol 1971; 48:262.</a></li></ol></div><div id="topicVersionRevision">Topic 7529 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19257881" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : EAACI position paper on occupational rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24397491" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Occupational upper airway disease: how work affects the nose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23324747" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Non-IgE-mediated and irritant-induced work-related rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32653647" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Occupational Rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25430949" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Occupational rhinitis: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23390199" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Occupational asthma and occupational rhinitis: the united airways disease model revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15990785" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Progression of self-reported symptoms in laboratory animal allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12527633" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk of asthma among Finnish patients with occupational rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Occupational rhinitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21708054" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Update on occupational rhinitis and asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069559" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Epidemiology of occupational rhinitis: prevalence, aetiology and determinants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17347607" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : [Occupational rhinitis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14982511" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Frequency of allergic rhinitis to laboratory animals in university employees as confirmed by chamber challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15617662" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Respiratory effects in workers processing dried tobacco leaves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17872490" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The healthy worker effect in asthma: work may cause asthma, but asthma may also influence work.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15005769" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Respiratory allergy in apprentice bakers: do occupational allergies follow the allergic march?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657867" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Incidence of occupational rhinoconjunctivitis and risk factors in animal-health apprentices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19492657" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Allergic rhinitis in laboratory animal workers and its risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Occupational Rhinitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12269937" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Incidence and host determinants of work-related rhinoconjunctivitis in apprentice pastry-makers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9215937" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The risk of occupational rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19326505" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Rhinitis guidelines and implications for occupational rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1238037" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Laboratory animal dander allergy: I. An occupational disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1733454" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Allergy to laboratory animals: an epidemiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8828532" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cat and dog allergy and total IgE as risk factors of laboratory animal allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16234402" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Incidence of allergy and allergy symptoms among workers exposed to laboratory animals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6354022" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mediator release after nasal airway challenge with allergen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2582257" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Inflammatory mediators in late antigen-induced rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28977704" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Inflammatory proteins in nasal lavage of workers exposed to occupational agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31833858" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnostic approach to occupational rhinitis: the role of nasal provocation tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29624710" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Nasal hyperreactivity in rhinitis: A diagnostic and therapeutic challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7889805" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Occupational asthma and related respiratory disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12772943" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Occupational rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17303675" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Rhinitis and asthma symptoms in non-domestic cleaners from the Sao Paulo metropolitan area, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664253" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Occupation and adult onset of rhinitis in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17153017" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nonallergic occupational rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11182423" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Allergen and dust exposure as determinants of work-related symptoms and sensitization in a cohort of flour-exposed workers; a case-control analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12782493" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cytopathology of the nasal mucosa in chronic exposure to diesel engine emission: a five-year survey of Swiss customs officers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7348692" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Respiratory tract reactions to western red cedar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10414417" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Allergen exposure, atopy and smoking as determinants of allergy to rats in a cohort of laboratory employees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11488324" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Natural history of sensitization, symptoms and occupational diseases in apprentices exposed to laboratory animals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18325579" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A comparison of skin prick tests, intradermal skin tests, and specific IgE in the diagnosis of mouse allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23409759" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : EAACI position paper: skin prick testing in the diagnosis of occupational type I allergies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23409759" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : EAACI position paper: skin prick testing in the diagnosis of occupational type I allergies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2651505" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Rhinomanometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437680" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Nasonasal reflexes, the nasal cycle, and sneeze.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acoustic rhinomanometry in the diagnosis of occupational rhinitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17882918" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Reproducibility of acoustic rhinometry in the investigation of occupational rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21303376" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Occupational rhinitis in bell pepper greenhouse workers: determinants of leaving work and the effects of subsequent allergen avoidance on health-related quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23618893" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prospective outcome assessment of occupational rhinitis after removal from exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16520669" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Occupational rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14719999" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The dilemma of occupational rhinitis: management options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Occupational Rhinitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743562" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17493066" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316891" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : [Specific immunotherapy in inhalative allergy to rat epithelium].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858747" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term exposure and health-related quality of life among patients with occupational rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29411403" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Occupational rhinitis and occupational asthma: Association or progression?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21557751" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : EAACI position paper: prevention of work-related respiratory allergies among pre-apprentices or apprentices and young workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19201013" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Associations between pre-employment immunologic and airway mucosal factors and the development of occupational allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3819230" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Occupational asthma and rhinitis related to laboratory rats: serum IgG and IgE antibodies to the rat urinary allergen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23176873" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Environmental assessment and exposure reduction of rodents: a practice parameter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4255272" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sensitivity to enzyme additives in laundry detergent workers.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
